Neogenomics Inc. (NASDAQ: NEO)’s stock price has increased by 0.66 compared to its previous closing price of 13.68. However, the company has seen a -5.17% decrease in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-03-20 that NeoGenomics (NEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is It Worth Investing in Neogenomics Inc. (NASDAQ: NEO) Right Now?
NEO has 36-month beta value of 1.12. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 4 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for NEO is 126.18M, and currently, short sellers hold a 5.74% ratio of that float. The average trading volume of NEO on April 19, 2024 was 899.44K shares.
NEO’s Market Performance
NEO’s stock has seen a -5.17% decrease for the week, with a -6.45% drop in the past month and a -11.33% fall in the past quarter. The volatility ratio for the week is 3.96%, and the volatility levels for the past 30 days are at 4.12% for Neogenomics Inc. The simple moving average for the past 20 days is -7.03% for NEO’s stock, with a -11.12% simple moving average for the past 200 days.
Analysts’ Opinion of NEO
Many brokerage firms have already submitted their reports for NEO stocks, with BTIG Research repeating the rating for NEO by listing it as a “Buy.” The predicted price for NEO in the upcoming period, according to BTIG Research is $21 based on the research report published on December 29, 2023 of the previous year 2023.
Stephens, on the other hand, stated in their research note that they expect to see NEO reach a price target of $18. The rating they have provided for NEO stocks is “Overweight” according to the report published on August 21st, 2023.
NEO Trading at -8.91% from the 50-Day Moving Average
After a stumble in the market that brought NEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.11% of loss for the given period.
Volatility was left at 4.12%, however, over the last 30 days, the volatility rate increased by 3.96%, as shares sank -11.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.90% lower at present.
During the last 5 trading sessions, NEO fell by -5.17%, which changed the moving average for the period of 200-days by -12.74% in comparison to the 20-day moving average, which settled at $14.72. In addition, Neogenomics Inc. saw -14.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NEO starting from TETRAULT LYNN A., who sale 6,112 shares at the price of $15.97 back on Mar 04 ’24. After this action, TETRAULT LYNN A. now owns 50,062 shares of Neogenomics Inc., valued at $97,579 using the latest closing price.
Olivo Alicia C, the General Counsel of Neogenomics Inc., sale 2,587 shares at $14.96 during a trade that took place back on Feb 15 ’24, which means that Olivo Alicia C is holding 34,866 shares at $38,713 based on the most recent closing price.
Stock Fundamentals for NEO
Current profitability levels for the company are sitting at:
- -0.17 for the present operating margin
- 0.41 for the gross margin
The net margin for Neogenomics Inc. stands at -0.15. The total capital return value is set at -0.07. Equity return is now at value -9.07, with -5.14 for asset returns.
Based on Neogenomics Inc. (NEO), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at -0.0. The debt to equity ratio resting at 0.65. The interest coverage ratio of the stock is 20.01.
Currently, EBITDA for the company is -6.52 million with net debt to EBITDA at -41.29. When we switch over and look at the enterprise to sales, we see a ratio of 3.43. The receivables turnover for the company is 4.51for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.20.
Conclusion
To put it simply, Neogenomics Inc. (NEO) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
